LUNG · Pulmonx Corp
Market Cap
$82.03M
Shares
42.95M
Volume · Oct 1
166.79K
Avg daily vol (3M)
475.76K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.91
Open$1.89
Day$1.87–1.93
52W close$1.17–2.60
Avg vol 30d318K
Short int848K · 2.0% float · 2.5d
Short vol53%
Last earningsJul 29, 2026
DataOct 2020–Oct 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 5 wks
filed Aug 4, 2026
call held Jul 29, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$87.44M
Trailing 12 months
Net income (TTM)
−$48.12M
Trailing 12 months
Revenue growth YoY
-4.6%
Year over year
Operating margin
-53.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-37.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$18.31M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.0%
Year over year · more shares
Price change (1Y)
+17.9%
Trailing year
Short interest
2.0%
Latest settlement · 2.5 days to cover
AI Brief
Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26
TL;DR. Pulmonx reported Q2 2026 revenue of $22.8M (down 5% YoY) with U.S. revenue down 4% and international down 6% due to the China shipment suspension, while delivering record 78% gross margin, a ~39% reduction in adjusted EBITDA loss, and reaffirming full-year revenue guidance of $90–92M with new full-year gross margin guidance of ~76% and opex guidance of $109–111M.
Bullish
- + Adjusted EBITDA loss narrowed by ~39% YoY to $5.1M, demonstrating operating leverage from cost realignment
- + Gross margin reached a record 78%, up from 72% in Q2 2025, on supply-chain efficiencies and mix
- + Net loss improved 34% YoY to $10.1M and operating expenses fell 16% YoY to $26.8M
- + Restructured credit facility extends maturity to 2031 and provides up to $20M of additional undrawn capital
- + Full-year 2026 cash burn expected at ~$23M, a nearly 30% reduction from 2025 burn
Bearish
- − Total worldwide revenue declined 5% YoY to $22.8M (6% on a constant currency basis)
- − U.S. revenue declined 4% YoY to $14.2M as new reps still ramp
- − International revenue declined 6% YoY due entirely to zero China shipments
- − China distributor shipments not expected to resume materially until early next year
- − Typical Q2-to-Q3 seasonality expected to weigh on sequential revenue
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
−6%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
52%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
+39%
trailing
YTD return
−14%
this year
Relative strength
+27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$177.0K over 90 days · 100% sells
Short interest
Falling
1.97% of float · ▼ -13.2% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
107 holders — near 3-yr low, contrarian setup
Squeeze score
48
elevated · 0–100
Fundamentals
Revenue growth
+8%
Y/Y
Gross margin
74%
expanding
EPS growth
+8%
Y/Y
Free cash flow
$-32.8M
Balance sheet
$32.7M
net cash
Quant / Vol
risk profile
Volatility
96%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jul 29, 2026
Full year 2026 revenue
· full year 2026
Initiated
$90M – $92M
prior FY $90.5M
midpoint +0.6% Y/Y
Cash burn
· full year 2026
Initiated
$23M
Guided vs delivered
· last 5 settled
Revenue
full year 2024
guided $81M – $84M
$83.79M
In line
Revenue
full year 2023
guided $67M – $68M
$68.68M
Beat +1.7%
Full year 2021 revenue
full year 2021
guided $49M – $51M
$48.42M
Miss −3.2%
First quarter revenue
first quarter 2021
guided $8M – $8.3M
$9.24M
Beat +13.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
−6%
Bearish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
52%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-6% holders QoQ · +19 funds added
Insider flow
Distributing
Net -$177.0K over 90 days · 100% sells
Short interest
Falling
1.97% of float · ▼ -13.2% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
107 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $2 · 52%
Range high $3
vs 200-day avg +13%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LUNG
this stock
Pulmonx Corp
|
$82.03M | -13.6% | +8.0% | — | 2.0% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.8% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.0% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -22.3% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.7% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LUNG | +0.5% | -16.2% | +39.4% | +0.0% | -13.6% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +1.0% | -16.1% | +27.0% | -0.2% | -25.6% |